secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001725160-25-000147
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports Q2 2025 cash of $303.4M; DENALI Phase 2 on track for topline by end 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $303.4M as of June 30, 2025; runway extended into late 2027.
- R&D expenses fell to $27.6M from $48.4M YoY; G&A expenses fell to $8.4M from $16.7M YoY.
- DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC remains on track; topline data expected by year-end 2026.
- Strategic restructuring completed; no further non-recurring expenses expected.
- Part 2 data, if successful, could support accelerated approval subject to FDA feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/0001725160-25-000147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/zntl-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer